Hospital
Providence Health & Services MT
Providence Health & Services MT was paid $2.42M by Medicaid between Jan 2018 and Dec 2024, across 304 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH & SERVICES MT
MISSOULA, MT 59802
MISSOULA, MT 59802
33aNPI1023032588assigned 07/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.42M
24GClaims887,721
24DCodes billed304
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Montana
Rank by total paid#3 of 10
Median peer was paid$774K
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,375 | $401K | |
| 2019 | 146,853 | $456K | |
| 2020 | 118,163 | $325K | |
| 2021 | 143,930 | $293K | |
| 2022 | 128,777 | $336K | |
| 2023 | 122,063 | $380K | |
| 2024incomplete | 83,560 | $234K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 27,408 | 23,798 | $335K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 23,297 | 20,184 | $294K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 16,624 | 14,708 | $254K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.8% | 6,181 | 5,629 | $116K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.0% | 5,704 | 4,768 | $96K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 2.8% | 9,831 | 8,687 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.6% | 9,137 | 7,816 | $64K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.6% | 1,381 | 1,143 | $62K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.4% | 1,559 | 1,341 | $59K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.2% | 2,171 | 1,958 | $53K |
| G0378 | Hospital observation service, per hour | 2.1% | 5,427 | 2,454 | $50K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 5,149 | 4,766 | $42K |
292 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 4,106 | $39K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 14,166 | $37K |
| 80053 | Comprehensive metabolic panel | 1.3% | 53,662 | $31K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 9,294 | $28K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 7,352 | $27K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.0% | 1,775 | $25K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,959 | $21K |
| J2704 | Injection, propofol, 10 mg | <1% | 11,011 | $20K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,761 | $19K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,856 | $19K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,222 | $17K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,227 | $17K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,196 | $16K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 241 | $16K |
| 76830 | Ultrasound, transvaginal | <1% | 3,302 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 53,735 | $15K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,187 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,121 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,942 | $14K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,932 | $14K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,053 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,077 | $13K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 459 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,858 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,249 | $12K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,198 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,451 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,354 | $10K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,442 | $10K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 4,810 | $9K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 12,450 | $9K |
| 88342 | <1% | 1,464 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,796 | $9K |
| 87070 | <1% | 3,095 | $8K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 543 | $8K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,560 | $8K |
| 82728 | <1% | 4,190 | $8K | |
| 73610 | <1% | 1,467 | $7K | |
| 88304 | <1% | 1,009 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,383 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,626 | $7K |
| 82077 | <1% | 3,959 | $7K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 845 | $6K |
| 81001 | <1% | 11,676 | $6K | |
| 80143 | <1% | 2,717 | $6K | |
| 96376 | <1% | 3,687 | $6K | |
| 80179 | <1% | 2,711 | $6K | |
| 73130 | <1% | 1,057 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,432 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,435 | $5K |
| 72141 | <1% | 1,096 | $5K | |
| 80061 | Lipid panel | <1% | 9,965 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,838 | $5K |
| 87186 | <1% | 3,617 | $5K | |
| 85027 | <1% | 13,043 | $5K | |
| 87077 | <1% | 4,017 | $5K | |
| 83690 | <1% | 8,413 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,829 | $5K |
| 84703 | <1% | 3,255 | $5K | |
| 12001 | <1% | 459 | $5K | |
| 81025 | <1% | 5,329 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,464 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,151 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,774 | $4K |
| 83540 | <1% | 1,986 | $4K | |
| 93971 | <1% | 1,133 | $4K | |
| 87040 | <1% | 1,244 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 397 | $4K |
| 73110 | <1% | 696 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 520 | $4K |
| 73630 | <1% | 1,309 | $4K | |
| 87081 | <1% | 2,327 | $4K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 750 | $4K |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,958 | $3K |
| 76770 | <1% | 382 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,436 | $3K |
| 86140 | <1% | 4,521 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,722 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,397 | $3K |
| 73562 | <1% | 1,316 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,171 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,388 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 83 | $3K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,582 | $3K |
| 83550 | <1% | 1,839 | $3K | |
| 73030 | <1% | 1,453 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 5,201 | $3K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 18,146 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,391 | $3K |
| 85652 | <1% | 3,372 | $3K | |
| 74018 | <1% | 725 | $3K | |
| 72040 | <1% | 1,217 | $3K | |
| 87205 | <1% | 2,661 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,942 | $2K |
| 72100 | <1% | 1,509 | $2K | |
| 74183 | <1% | 401 | $2K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,765 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,566 | $2K |
| 84439 | <1% | 3,633 | $2K | |
| 84484 | <1% | 7,990 | $2K | |
| 95811 | <1% | 674 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 396 | $2K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 19 | $2K |
| 88307 | <1% | 952 | $2K | |
| 76536 | <1% | 383 | $2K | |
| 87075 | <1% | 1,097 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 13 | $2K |
| 83605 | <1% | 1,186 | $2K | |
| 97161 | <1% | 1,482 | $2K | |
| 93226 | <1% | 135 | $2K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,277 | $2K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,592 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,466 | $2K |
| 82607 | <1% | 2,245 | $1K | |
| 70498 | <1% | 421 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,045 | $1K |
| J3490 | Unclassified drugs | <1% | 513 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,773 | $1K |
| 93225 | <1% | 135 | $1K | |
| 70496 | <1% | 375 | $1K | |
| C1769 | Guide wire | <1% | 2,685 | $1K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 368 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 886 | $1K |
| 71250 | <1% | 960 | $1K | |
| 99152 | <1% | 1,137 | $1K | |
| 85379 | <1% | 2,107 | $1K | |
| 95816 | <1% | 131 | $1K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,636 | $1K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 343 | $1K |
| 87210 | <1% | 1,682 | $1K | |
| 73080 | <1% | 71 | $946.28 | |
| 12011 | <1% | 24 | $938.37 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,650 | $927.93 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 427 | $890.06 |
| 76642 | <1% | 1,280 | $883.67 | |
| 87427 | <1% | 369 | $871.20 | |
| 80076 | <1% | 407 | $868.11 | |
| 83735 | <1% | 2,903 | $836.44 | |
| 94729 | <1% | 964 | $803.74 | |
| 94726 | <1% | 801 | $782.85 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 951 | $743.59 |
| 85610 | <1% | 11,923 | $736.01 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,411 | $709.79 |
| 90715 | <1% | 499 | $702.73 | |
| 82962 | <1% | 9,119 | $656.40 | |
| 82570 | <1% | 1,626 | $653.07 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 646 | $650.12 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 724 | $649.96 |
| 0352U | <1% | 317 | $637.50 | |
| 94060 | <1% | 416 | $633.72 | |
| 93017 | <1% | 1,818 | $620.69 | |
| 11043 | <1% | 19 | $586.50 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,777 | $575.39 |
| 86850 | <1% | 1,550 | $562.16 | |
| 87046 | <1% | 208 | $556.49 | |
| 87045 | <1% | 207 | $528.15 | |
| 76870 | <1% | 25 | $483.65 | |
| 86901 | <1% | 1,810 | $475.42 | |
| 86900 | <1% | 1,804 | $455.77 | |
| 93242 | <1% | 766 | $455.49 | |
| 86803 | <1% | 2,197 | $437.71 | |
| 88300 | <1% | 116 | $423.29 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 519 | $411.32 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 76 | $407.97 |
| 85730 | <1% | 1,368 | $391.16 | |
| 73502 | <1% | 183 | $387.60 | |
| 87420 | <1% | 114 | $377.10 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 761 | $376.26 |
| 83880 | <1% | 1,579 | $370.76 | |
| 97116 | <1% | 2,099 | $360.45 | |
| J1815 | Injection, insulin, per 5 units | <1% | 851 | $356.83 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,038 | $350.43 |
| 77080 | <1% | 312 | $346.62 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 373 | $339.71 |
| 59025 | Fetal non-stress test | <1% | 62 | $337.67 |
| 0240U | <1% | 52 | $327.24 | |
| 73620 | <1% | 283 | $326.40 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 684 | $313.91 |
| 82043 | <1% | 1,361 | $307.09 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 1,715 | $292.90 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,589 | $284.75 |
| 81003 | <1% | 738 | $265.53 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 460 | $261.43 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,400 | $254.15 |
| 97162 | <1% | 918 | $239.03 | |
| 94010 | <1% | 97 | $238.96 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 177 | $231.02 |
| 87899 | <1% | 203 | $227.25 | |
| 72020 | <1% | 157 | $208.03 | |
| 82550 | <1% | 339 | $207.12 | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 24 | $206.60 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,213 | $202.48 |
| 0296T | <1% | 133 | $192.95 | |
| 73140 | <1% | 25 | $192.32 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,873 | $182.23 |
| 12002 | <1% | 26 | $172.66 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 425 | $168.75 |
| 86706 | <1% | 71 | $165.74 | |
| 84100 | <1% | 919 | $157.44 | |
| 82565 | <1% | 2,702 | $151.04 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 291 | $139.51 |
| 80047 | <1% | 133 | $138.97 | |
| 83615 | <1% | 1,121 | $135.99 | |
| 84702 | <1% | 128 | $130.05 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,337 | $127.58 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,358 | $126.71 |
| 80164 | <1% | 330 | $122.40 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 12 | $101.99 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 52 | $96.81 |
| 97542 | <1% | 498 | $95.85 | |
| 86592 | <1% | 106 | $91.80 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,325 | $82.29 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 332 | $75.78 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 545 | $74.38 |
| 97165 | <1% | 55 | $64.82 | |
| 87340 | <1% | 367 | $57.81 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 49 | $48.40 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 13,430 | $38.19 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,112 | $33.53 |
| 73120 | <1% | 369 | $32.48 | |
| 93325 | <1% | 845 | $25.77 | |
| 85014 | <1% | 434 | $25.36 | |
| 77065 | Tomosynthesis, mammo | <1% | 132 | $21.70 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 526 | $21.22 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 144 | $17.90 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 331 | $16.16 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,347 | $14.06 |
| A9270 | Non-covered item or service | <1% | 7,234 | $12.04 |
| 80178 | <1% | 381 | $10.21 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 136 | $5.29 |
| 85055 | <1% | 86 | $1.70 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 841 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 151 | $0.00 |
| 82274 | 0% | 60 | $0.00 | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 0% | 4,053 | $0.00 |
| 96417 | 0% | 241 | $0.00 | |
| 93350 | 0% | 168 | $0.00 | |
| 97167 | 0% | 84 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 32 | $0.00 |
| 96367 | 0% | 322 | $0.00 | |
| 93798 | 0% | 509 | $0.00 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 0% | 316 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 118 | $0.00 |
| 97129 | 0% | 227 | $0.00 | |
| 71271 | 0% | 69 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 35 | $0.00 |
| 84550 | 0% | 88 | $0.00 | |
| 77066 | Tomosynthesis, mammo | 0% | 173 | $0.00 |
| 77077 | 0% | 36 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 124 | $0.00 |
| 74178 | 0% | 16 | $0.00 | |
| 76882 | 0% | 51 | $0.00 | |
| 82140 | 0% | 46 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 29 | $0.00 |
| 43235 | 0% | 36 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 15 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 18 | $0.00 |
| 89051 | 0% | 13 | $0.00 | |
| 83970 | 0% | 14 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 3,323 | $0.00 |
| 93320 | 0% | 424 | $0.00 | |
| 84153 | 0% | 768 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 2,486 | $0.00 |
| 36591 | 0% | 1,070 | $0.00 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | 0% | 1,381 | $0.00 |
| 97130 | 0% | 207 | $0.00 | |
| 85018 | 0% | 85 | $0.00 | |
| J1610 | Injection, glucagon hydrochloride, per 1 mg | 0% | 246 | $0.00 |
| 97035 | 0% | 917 | $0.00 | |
| 96415 | 0% | 223 | $0.00 | |
| 82746 | 0% | 25 | $0.00 | |
| 93458 | 0% | 43 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 168 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 176 | $0.00 |
| C8928 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report | 0% | 68 | $0.00 |
| 93270 | 0% | 14 | $0.00 | |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 25 | $0.00 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 0% | 17 | $0.00 |
| 72170 | 0% | 16 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 170 | $0.00 |
| 70486 | 0% | 12 | $0.00 | |
| 94762 | 0% | 14 | $0.00 | |
| 73221 | 0% | 13 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 40 | $0.00 |
| 82378 | 0% | 14 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 45 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 19 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 18 | $0.00 |
| 82150 | 0% | 14 | $0.00 | |
| 72126 | 0% | 17 | $0.00 | |
| 72146 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
Parent organizationPROVIDENCE HEALTH & SERVICES
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.